Infos und quasi Blog

The association between prenatal exposure to cannabis with and without tobacco and early cognitive and language development in a sample of polysubstance-exposed children Source / Quelle: https://www.sciencedirect.com/science/article/pii/S0378378226000745?via%3Dihub Highlights • We tested whether children with prenatal cannabis and/or tobacco exposure had worse development. • Cannabis exposure was not associated with impaired cognitive or language development. • Co-exposure to tobacco was not associated with worse outcomes than cannabis alone. • Results may help reduce stigma among women who have used cannabis during pregnancy. Abstract Background Prenatal cannabis exposure may have adverse effects on development which could be amplified by co-exposure with tobacco. Objective This study examined whether prenatal cannabis exposure was associated with disrupted language or cognitive development, and whether co-exposure to tobacco was associated with worse outcomes than to cannabis alone.

Source / Quelle: https://www.ecoeet.com/Cannabis-sativa-L-leaf-by-products-extracts-Chemical-composition-antimicrobial-and,220997,0,1.html Summary Aims: This study aimed to evaluate the biological potential of Cannabis sativa L. leaf co-products obtained through different extraction methods (sonication, maceration, and decoction), with a particular focus on their antimicrobial properties and chemical composition. Methodology and Results: Extracts were prepared using sonication, maceration, and decoction, and their antimicrobial activity was assessed against two pathogenic microorganisms: Aggregatibacter actinomycetemcomitans and Candida albicans. The sonication extract exhibited the highest antibacterial activity against A. actinomycetemcomitans, whereas the maceration extract showed strong antifungal activity against C. albicans. All extracts, except the decoction, demonstrated both bactericidal and fungicidal effects. Chemical characterization was performed using High-Performance Liq

Source / Quelle: https://www.ajpmonline.org/article/S0749-3797(26)00164-9/abstract Abstract Introduction Many young adults vape and smoke cannabis, but it remains unclear whether dual use increases the risk of respiratory problems. Methods This study analyzed the national longitudinal Population Assessment of Tobacco and Health Study. The sample included 5,211 young adults (aged 18–24 years) without prior respiratory or pulmonary conditions at Wave 6 who completed Wave 7. Multivariable logistic regressions examined longitudinal associations between baseline cannabis vaping and smoking and functionally important respiratory symptoms at follow-up, controlling for sociodemographics, other substance use, health conditions, obesity, and cannabis use frequency. Data were collected between 2021 and 2023 and analyzed in 2025. Results At baseline, 18.8% of young adults reported past 30-day cannabis vaping or smoking: 2.1% vaped only, 11.3% smoked only, and 5.3% both vaped and smoked. Overall, 2

Source / Quelle: https://pmc.ncbi.nlm.nih.gov/articles/PMC5576600/ Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy Abstract Cannabidiol (CBD), the main nonpsychoactive constituent of Cannabis sativa, has shown a wide range of therapeutically promising pharmacological effects either as a sole drug or in combination with other drugs in adjunctive therapy. However, the targets involved in the therapeutic effects of CBD appear to be elusive. Furthermore, scarce information is available on the biological activity of its human metabolites which, when formed in pharmacologically relevant concentration, might contribute to or even account for the observed therapeutic effects. The present overview summarizes our current knowledge on the pharmacokinetics and metabolic fate of CBD in humans, reviews studies on the biological activity of CBD metabolites either in vitro or in vivo, and discusses relevant drug–drug interactions. To facilit

Source / Quelle: https://jintb.org/index.php/jintb/article/view/30 Abstract Inflammation and oxidative stress contribute to numerous human diseases. Conventional therapies provide symptomatic relief but fail to address molecular dysfunction. Cannabinoids emerge as promising modulators of these processes, influencing CB1/2 receptor signaling, regulating NF-κB and Nrf2 pathways, and reactive oxygen species production. Preclinical studies demonstrate them to reduce cytokine release, limit oxidative damage, and protect tissue integrity across multiple systems. Early clinical investigations suggest potential benefits in pain management, neurodegeneration, and metabolic conditions. Future research focusing on minor and synthetic cannabinoids, biomarker-guided dosing, and combination therapies can enhance translational success, but regulatory and safety considerations remain critical. By bridging mechanistic insights with clinical application, cannabinoids hold significant potential to addres

Source / Quelle: https://www.mdpi.com/1424-8247/19/4/560 Abstract Background/Objectives: Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease that primarily affects the joints. Current treatments aim to relieve pain and limit joint damage; however, many are associated with significant side effects or high costs. Neutrophils play a critical role in RA development and progression by driving synovial inflammation and tissue damage, yet no approved therapies directly target neutrophil-mediated pathogenic mechanisms. Cannabinoids have demonstrated anti-inflammatory potential. Although cannabinoids have been studied in RA, the direct modulation of neutrophil-driven mechanisms by purified CBG has not been systematically addressed. To harness the cannabinoid potential, we investigated the effects of the purified cannabinoid Cannabigerol (CBG) on neutrophil-mediated immune responses in RA. Methods: We assessed the effects of CBG on human blood isolated neutrophil cytokine se